TWI BIOTECHNOLOGY, INC.

Highlights TWi Biotechnology, Inc.

Equities

6610

TW0006610009

End-of-day quote Taipei Exchange Other stock markets 23:00:00 27/06/2024 BST			5-day change	1st Jan Change
15.15 ^TWD	-1.94%		+10.99%	+8.21%

04-09	TWi Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	TWi Biotechnology, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	CI

Highlights

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

TWi Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-08	CI
TWi Biotechnology, Inc. Reports Earnings Results for the Half Year Ended June 30, 2023	13/08/23	CI
TWi Biotechnology, Inc. Exploring Promising Treatment for Granuloma Annulare (Ga)	02/06/23	CI
TWi Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	26/04/23	CI
TWi Biotechnology, Inc. Reports Earnings Results for the Half Year Ended June 30, 2022	11/08/22	CI
TWi Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	27/04/22	CI
Twi Biotechnology, Inc. Reports Earnings Results for the Half Year Ended June 30, 2021	14/08/21	CI
Winhealth Pharma and TWiB Enter into Strategic Licensing Partnership on AC-203	07/01/21	CI
Twi Biotechnology, Inc. Reports Earnings Results for the Half Year Ended June 30, 2020	12/08/20	CI
TWi Biotechnology Receives Canada Health Approval for AC-1101 Phase 1 CTA	07/05/20	CI
Twi Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2018	09/04/19	CI
TWi Biotechnology, Inc. Announces Last Patient Enrolled in Phase 2 Study of AC-201CR for Treatment of Hemophilic Arthropathy	15/11/18	CI
TWi Biotechnology, Inc. Announces Initiation of Phase 2 Proof-of-Concept Clinical Trial of AC-203 for Treatment of Inherited Epidermolysis Bullosa	20/10/18	CI
TWi Biotechnology, Inc. Announces Regulatory Clearance to Begin Phase 2 Proof-of-Concept Clinical Trial of AC-203 for Treatment of Inherited Epidermolysis Bullosa	26/02/18	CI
TWi Biotechnology Inc. Announces Last Patient Enrolled in Phase 2 Study of AC-201CR for Gout Treatment	27/06/16	CI
TWi Biotechnology, Inc. Enters Development and Commercialization Agreement and Collaboration with Castle Creek Pharmaceuticals	22/12/15	CI
TWi Biotechnology, Inc. Completes Multinational Phase II Dose-Ranging Study of AC-201	06/08/12	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Protect and grow your investments with the help of our experts

Securing my Investments

fermer